Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer

Table 2 Summary of chemotherapy toxicity n (%)

Characteristic	Folfiri 3 (n = 18)	Bevacizumab folfiri 3 (n = 99)	Aflibercept folfiri 3 (n = 36)	All (n = 153)
Anemia
No	14	79	29	122
Grade 1	2	10	5	17
Grade 2	0	8	0	8
Grade 3	2	1	2	5
Grade 4	0	1	0	1
Thrombopenia
No	17	91	31	139
Grade 1	0	5	3	8
Grade 2	0	2	0	2
Grade 3	1	0	0	1
Grade 4	0	1	2	3
Neutropenia
No	13	87	26	126
Grade 1	1	0	1	2
Grade 2	2	1	4	7
Grade 3	1	9	4	14
Grade 4	1	2	1	4
Diarrheoa
No	9	48	11	68
Grade 1	2	18	8	28
Grade 2	5	14	5	24
Grade 3	2	14	11	27
Grade 4	0	5	1	6
Stomitis
No	13	83	27	123
Grade 1	2	5	5	12
Grade 2	2	8	4	14
Grade 3	0	1	0	1
Grade 4	1	2	0	3
Nausea
No	17	81	28	126
Grade 1	1	8	5	14
Grade 2	0	10	3	13
Vomiting
No	17	90	31	138
Grade 1	0	3	4	7
Grade 2	0	3	1	4
Grade 3	1	3	0	4
Hyperblood pressure
No	18	98	36	152
Yes	0	1	0	1
Bleeding
No	17	95	30	142
Yes	1	4	6	11
Venous thrombosis
No	18	97	36	151
Yes	0	2	0	2
Digestive perforation
No	18	98	36	152
Yes	0	1	0	1